Racial Disparities in HIV and Syphilis Vary Widely by State

Article

A new analysis finds racial and ethnic disparities vary significantly from state to state when it comes to sexually transmitted infection rates among men who have sex with men.

Patrick Sullivan, DVM, PhD

Patrick Sullivan, DVM, PhD

Black and Hispanic men who have sex with men (MSM) tend to have higher rates—sometimes much higher rates—of HIV and syphilis than their white counterparts, but a new analysis found that the size of the disparity varies considerably from one state to the next.

First author Patrick Sullivan, DVM, PhD, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, told MD Magazine® that several key factors can vary from state to state, leading to the high disparities.

“For example, factors like stigma, discrimination, and homophobia can shape risks for black and Hispanic MSM, and those factors may differ among states,” he said. “Similarly, socio-economic issues driven by poverty can result in less access to healthcare, problems with stable housing, or less access to education.”

Sullivan and colleagues sifted through state-level data from 2015 and 2016 in order to come up with estimates of HIV and syphilis rates among different racial and ethnic groups within states.

In the US overall, black MSM were more than 3 times as likely to be living with HIV compared to non-Hispanic white men, and 5 times more likely to be diagnosed with HIV. Meanwhile, Hispanic men were nearly twice as likely (rate ratio [RR] of 1.72) as non-Hispanic white men to have HIV and nearly 3 times as likely (RR 2.97) to receive an HIV diagnosis.

However, black MSM in Rhode Island were only 2.35 times more likely than white MSM to receive a new HIV diagnosis, the lowest of any state rate ratio. In Wisconsin, which had the highest disparity, black MSM were more than 10 times as likely to be diagnosed with HIV. Among Hispanic men compared to non-Hispanic white men, Tennessee had the lowest disparity (RR 1.50) and Pennsylvania had the highest disparity (RR 5.78).

Syphilis rates also varied significantly. The biggest gap was between black MSM and white MSM in Alaska, where black MSM were 17 times more likely to be diagnosed with syphilis. Meanwhile, in the District of Columbia, black MSM were slightly less likely (RR .8) than white MSM to be diagnosed with the sexually transmitted infection.

Though this paper did not specifically look at Medicaid expansion, Sullivan said previous research has shown that states that did not expand Medicaid had lower rates of pre-exposure prophylaxis (PrEP) use, and thus it would follow that those states might have higher rates of HIV diagnoses.

Sullivan said states with the highest disparities ought to undertake a self-evaluation centered around several questions.

“First, are the prevention resources aligned with the communities where the impact is greatest?” he said. “Are the interventions being provided optimal for the specific groups at greatest risk? Are they being delivered in the parts of the community where the disparity population is most concentrated?”

Sullivan said states should also check in with local planning bodies to see how interventions are being delivered and whether there is a gap between expected and actual efficacy.

“Addressing disparities should represent a cycle that measures and recognizes disparities, seeks information from within communities about whether programs are reaching those at greatest risk, attempts to adjust where and how programs are implemented, and continues to re-evaluate and monitor the impacts,” he said.

The study, “Patterns of Racial/Ethnic Disparities and Prevalence in HIV and Syphilis Diagnoses Among Men Who Have Sex With Men, 2016: A Novel Data Visualization,” was published in the American Journal of Public Health.

Related Videos
Nanette B. Silverberg, MD: Uncovering Molluscum Epidemiology
A Year of RSV Highs and Lows, with Tina Tan, MD
Ryan A. Smith, MD: RSV Risk in Patients with IBD
Cedric Rutland, MD: Exploring Immunology's Role in Molecule Development
Cedric Rutland, MD: Mechanisms Behind Immunology, Cellular Communication
Glenn S. Tillotson, PhD: Treating Immunocompromised Patients With RBX2660
Paul Feuerstadt, MD: Administering RBX2660 With a Colonoscopy
Jessica Allegretti, MD, MPH: Evaluating the First Few Months of RBX2660
Naim Alkhouri, MD: Improving NASH Diagnosis With FibroScan
© 2024 MJH Life Sciences

All rights reserved.